Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification

Journal of the National Cancer Institute

Volumn 86, Issue 17, 1994, Pages 1331-1335

  Habuchi, Tomonori ^a   Kinoshita, Hidefumi ^a   Yamada, Hitoshi ^a   Kakehi, Yoshiyuki ^a   Ogawa, Osamu ^a   Wu, Wen Jeng ^a   Takahashi, Rei ^a   Sugiyama, Taketoshi ^a   Yoshida, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; DNA CONFORMATION; DNA DETERMINATION; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PROTO ONCOGENE; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT CANCER;

BLOTTING, SOUTHERN; CARCINOMA, TRANSITIONAL CELL; DNA PROBES; GENE AMPLIFICATION; GENES, P53; HUMAN; MUTATION; NEOPLASM PROTEINS; PROTO-ONCOGENES; SUPPORT, NON-U.S. GOV'T; UROLOGIC NEOPLASMS;

EID: 0028129547     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/86.17.1331     Document Type: Article

References (52)

1. Levine AJ, Momand J, Finley CA: The p53 tumour suppressor gene. Nature 351:453-456. 1991 Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
2. Olumi AF, Tsai YC, Nichols PW, et al: Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 50:70817083, 1990
3. Sidransky D, von Eschenbach A, Tsai YC, et al: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-709, 1991
4. Presti JC Jr, Reuter VE, Galan T, et al: Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 51:5405-5409, 1991
5. Habuchi T, Ogawa O, Kakehi Y, et al: Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer 53:579-584, 1993
6. Spruck CH 3rd, Ohneseit PF, Gonzalez- Zulueta M, et al: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784-788, 1994
7. Habuchi T, Takahashi R, Yamada H, et al: Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 53:3795-3799, 1993
8. Kastan MB, Onyekwere O, Sidransky D, et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311, 1991
9. Fritsche M, Haessler C, Brandner G: Induction of nuclear accumulation of the tumour-suppressor protein p53 by DNA-damaging agents [published erratum appears in Oncogene 8:2605, 1993]. Oncogene 8:307-318, 1993
10. Kastan MB, Zahn Q, el-Deiry WS, et al: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597, 1992
11. Livingstone LR, White A, Sprouse J, et al: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992
12. Yin Y, Tainsky MA, Bischoff FZ, et al: Wild- type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948, 1992
13. Fakharzadeh SS, Trusko SP, George DL: Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:15651569, 1991
14. Oliner JD, Kinzler KW, Meltzer PS, et al: Amplification of a gene encoding a p53-asso- ciated protein in human sarcomas [see comment citation in Medline]. Nature 358:80-83, 1992
15. Eadanyi M, Cha C, Lewis R, et al: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53:16-18, 1993
16. Leach FS, Tokino T, Meltzer P, et al: p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231-2234, 1993
17. Reifenberger G, Liu L, Ichimura K, et al: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736-2739, 1993
18. Momand J, Zambetti GP, Olson DC, et al: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245, 1992
19. Oliner JD, Pietenpol JA, Thiagalingam S, et al: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860, 1993
20. Chen CY, Oliner JD, Zhan Q, et al: Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci U S A 91:2684-2688, 1994
21. Zhau HE, Zhang X, von Eschenbach AC, et al: Amplification and expression of the c-erb B- 2/neu proto-oncogene in human bladder cancer. Mol Carcinog 3:254-257, 1990
22. Coombs LM, Pigott DA, Sweeney E, et al: Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. BrJCancer 63:601-608, 1991
23. Theillet C, Le Roy X, De Lapeyriere O, et al: Amplification of FGF-related genes in human tumors: possible involvement of HST in breast carcinomas [published erratum appears in Oncogene 4:1537, 1989]. Oncogene 4:915-922, 1989
24. Proctor AJ, Coombs LM, Caims JP, et al: Amplification at chromosome 11 q 13 in transitional cell tumours of the bladder. Oncogene 6:789-795, 1991
25. Berger MS, Greenfield C, Gullick WJ, et al: Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer 56:533537, 1987
26. Fujita J, Srivastava SK, Kraus MH, et al: Frequency of molecular alterations affecting ras protooncogenes in human urinary tract tumors. Proc Natl Acad Sci U S A 82:3849-3853, 1985
27. Perucca D, Szepetowski P, Simon MP, et al: Molecular genetics of human bladder carcinomas. Cancer Genet Cytogenet 49:143-156, 1990
28. Mostofi FK, Sobin LH, Torloni H: Histological Typing of Urinary Bladder Tumours. Geneva: WHO, 1973.
29. Hermanek P, Sobin LH, eds: TNM Classification of Malignant Tumours, 4th ed., Geneva: International Union Against Cancer (UICC), 1987
30. Taya Y, Hosogai K, Hirohashi S, et al: A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer. EMBO J 3:2943-2946, 1984
31. Stanton LW, Schwab M, Bishop JM: Nucleotide sequence of the human N-myc gene. Proc Natl Acad Sci U S A 83:1772-1776, 1986
32. Nau MM, Brooks BJ, Battey J, et al: L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 318:69-73, 1985
33. Merlino GT, Ishii S, Whang-Peng J, et al: Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol Cell Biol 5:1722-1734, 1985
34. Semba K, Kamata N, Toyoshima K, et al: A v- erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A 82:6497-6501, 1985
35. Casey G, Smith R, McGillivray D, et al: Characterization and chromosome assignment of the human homolog of int-2, a potential protooncogene. Mol Cell Biol 6:502-510, 1986
36. Bonner TI, Kerby SB, Sutrave P, et al: Structure and biological activity of human homologs of the raf/mil oncogene. Mol Cell Biol 5:1400-1407, 1985
37. Santos E, Tronick SR, Aaronson SA, et al: T24 human bladder carcinoma oncogene is an activated form of the normal human homo- logue of BALB- and Harvey-MSV transforming genes. Nature 298:343-347, 1982
38. McCoy MS, Bargmann Cl, Weinberg RA: Human colon carcinoma Ki-ras2 oncogene and its corresponding proto-oncogene. Mol Cell Biol 4:1577-1582, 1984
39. Taparowsky E, Shimizu K, Goldfarb M, et al: Structure and activation of the human N-ras gene. Cell 34:581-586, 1983
40. Cooper CS, Park M, Blair DG, et al: Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29-33, 1984
41. Majello B, Kenyon LC, Dalla-Favera R: Human c-myb protooncogene: nucleotide sequence of cDNA and organization of the genomic locus. Proc Natl Acad Sci U S A 83:9636-9640, 1986
42. Watson R, Oskarsson M, Vande Woude GF: Human DNA sequence homologous to the transforming gene (mos) of Molony murine sarcoma virus. Proc Natl Acad Sci U S A 79:4078-4082, 1982
43. Gazit A, Igarashi H, Chiu IM, et al: Expression of the normal human sis/PDGF-2 coding sequence induces cellular transformation. Cell 39:89-97, 1984
44. Wong AJ, Ruppert JM, Eggleston J, et al: Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. Science 233:461-464, 1986
45. Gareau JL, Houle B, Leduc F, et al: A frequent Hin& lll RFLP on chromosome 3p21 -25 detected by a genomic erbA-|3 sequence. Nucleic Acids Res 16:1223, 1988
46. Nasmyth K, Hunt T: Dams and sluices [news; see comment citations in Medline], Nature 366:634-635, 1993
47. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85:5359, 1993
48. Livingstone LR, White A, Sprouse J, et al: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992
49. Dittmer D, Pati S, Zambetti G, et al: Gain of function mutations in p53. Nat Genet 4:42-46, 1993
50. Soussi T, Caron de Fromentel C, May P: Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952, 1990
51. Mazars R, Spinardi L, BenCheikh M, et al: p53 mutations occur in aggressive breast cancer. Cancer Res 52:3918-3923, 1992
52. Imamura J, Bartram CR, Berthold F, et al: Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res 53:4053-4058, 1993